Combination of Palbociclib and Endocrine Therapy in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With or Without Brain Metastases
CONCLUSIONS: Palbociclib plus endocrine therapy in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer was effective and well-tolerated, even in patients with brain metastases. More benefits were observed in frontline therapy, chemotherapy-naive, and endocrine therapy-sensitive patients with fewer metastatic sites.PMID:38233376 | PMC:PMC10798105 | DOI:10.1177/15330338231206986
Source: Technology in Cancer Research and Treatment - Category: Cancer & Oncology Authors: Qiuyi Zhang Xiaofeng Lan Jiayi Huang Xiaofeng Xie Liping Chen Lin Song Xue Bai Xuelian Chen Haiman Jing Caiwen Du Source Type: research
More News: Academies | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | China Health | Endocrine Therapy | Hong Kong Health | Hormones | Neurology | Palliative | Study